Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8263344
APP PUB NO 20100015653A1
SERIAL NO

12438975

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a method for determining the susceptibility of a patient tumor cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumor cell.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSTITUT GUSTAVE ROUSSYVILLEJUIF
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)101 RUE DE TOLBIAC PARIS 75013

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kroemer, Guido Antony, FR 36 155
Panaretakis, Theocharis Stockholm, SE 1 4
Zitvogel, Laurence Antony, FR 34 232

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation